98%
921
2 minutes
20
This study investigated the trends in idiopathic peptic ulcers, examined the characteristics of refractory idiopathic peptic ulcer, and identified the optimal treatment. The characteristics of 309 patients with idiopathic peptic ulcer were examined. We allocated idiopathic peptic ulcers that did not heal after 8 weeks' treatment (6 weeks for duodenal ulcers) to the refractory group and those that healed within this period to the healed group. The typical risk factors for idiopathic peptic ulcer (atherosclerosis-related underlying disease or liver cirrhosis complications) were absent in 46.6% of patients. Absence of gastric mucosal atrophy (refractory group: 51.4%, healed group: 28.4%; = 0.016), and gastric fundic gland polyps (refractory group: 17.6%, healed group: 5.9%; = 0.045) were significantly more common in the refractory group compared to the healed group. A history of eradication (refractory group: 85.3%, healed group: 66.0%; = 0.016), previous infection (i.e., gastric mucosal atrophy or history of eradication) (refractory group: 48.5%, healed group: 80.0%; = 0.001), and potassium-competitive acid blocker treatment (refractory group: 28.6%, healed group, 64.1%; = 0.001) were significantly more frequent in the healed group compared to the refractory group. Thus, acid hypersecretion may be a major factor underlying the refractoriness of idiopathic peptic ulcer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10822756 | PMC |
http://dx.doi.org/10.3164/jcbn.23-82 | DOI Listing |
Cell Death Discov
September 2025
Department of Molecular Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Ado-trastuzumab is considered a standard treatment for patients with HER2+ metastatic breast cancer (mBC). Current clinical practices do not reliably predict therapeutic outcomes for patients who are refractory to therapy. Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression and therapeutic resistance, and the use of lncRNAs as tumor biomarkers is becoming more common in other diseases.
View Article and Find Full Text PDFEpilepsy Behav
September 2025
Danone Research & Innovation, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands. Electronic address:
Purpose: Ketogenic diet therapy (KDT) has been successfully used as an effective management option for drug resistant epilepsy (DRE) since the 1920 s. The ketogenic formulation studied here (KetoCal) is nutritionally complete, very high in fat, and low in carbohydrates and has played a crucial role in supporting the implementation of KDT for over twenty-five years. This scoping review aims to synthesise the existing literature regarding the safety, acceptability, and efficacy of the ketogenic formulation in supporting the management of DRE.
View Article and Find Full Text PDFBlood
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Isatuximab is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multi-center, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis.
View Article and Find Full Text PDFArch Esp Urol
August 2025
Department of Urology, National Taiwan University Hospital, 10002 Taipei, Taiwan.
Objective: Conventional penile venous surgery for erection restoration and surgery for penile augmentation have been controversial. Based on de novo penile fibrovascular assembly, we report innovative penile venous stripping (PVS) and factual penile girth enhancement (FPGE).
Methods: From 2013 to 2023, refractory impotence and dysmorphia prompted 31 patients to seek PVS and FPGE, and all of them were confirmed with veno-occlusive dysfunction.
BMJ Open
September 2025
Arrhythmia Center, Chinese Academy of Medical Sciences Fuwai Hospital, Beijing, China.
Objectives: To evaluate the efficacy and safety of adding Superior Vena Cava Isolation (SVCI) to Pulmonary Vein Isolation (PVI) in patients with drug-refractory paroxysmal atrial fibrillation (PAF).
Design: Systematic review and meta-analysis of randomised controlled trials (RCTs) using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, supplemented with Trial Sequential Analysis (TSA) to assess evidence sufficiency.
Data Sources: We searched PubMed, EMBASE, the Cochrane Library (CENTRAL) and Web of Science for relevant studies published up to 13 July 2025.